Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
22 Novembro 2021 - 10:17AM
Business Wire
Biocept continues to expand and perform
COVID-19 testing services using Thermo Fisher Scientific
platform
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products, and services, now offers a single test
that can detect and distinguish between SARS-CoV-2 and influenza,
helping patients and caregivers determine appropriate treatment
decisions. This new assay expands the company’s COVID-19 testing
program, which began in June 2020 and has now received more than
670,000 samples for processing.
“As we navigate through a complicated flu season, expanding our
COVID-19 testing services to include influenza testing allows us to
better meet the needs of our customers and our communities,” said
Michael Nall, President and CEO of Biocept. “Because of the
similarities in symptoms, determining whether a patient has
COVID-19 or the seasonal flu can help patients and physicians make
decisions about care that may lead to reduced viral spread and more
efficient utilization of healthcare resources. This new offering
demonstrates our continued effort to support public health
initiatives and provide customers with the answers they need.”
Biocept’s combined COVID-19 and influenza testing uses a
sensitive and specific RT-PCR platform to detect and distinguish
between SARS-CoV-2 and influenza. Samples are collected through
nasal swab and processed through Biocept’s CLIA-certified,
CAP-accredited laboratory with results typically within
approximately 48 hours from receipt of sample, providing timely and
accurate results.
While Biocept continues to expand and perform COVID-19 testing
services with Thermo Fisher Scientific’s diagnostic platform and
kits, which are FDA approved, commercialization of the co-developed
AEGEA Biotechnologies COVID-19 assay will be delayed, as a result
of newly announced changes to FDA requirements for
laboratory-developed COVID-19 tests.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like “plan,” "may," "will,"
"anticipate," "believe," “long-term” or "project" or the negative
of these words or other variations on these words or comparable
terminology. To the extent that statements in this release are not
strictly historical, including without limitation statements
regarding anticipated demand for our combination COVID-19 and
seasonal influenza test and the capabilities and potential benefits
of such test, and our ability to provide physicians with clinically
actionable information, such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including: demand for our testing services may be lower than we
anticipate; we currently rely on third-party suppliers for blood
collection tubes, shipping kits, and critical materials needed to
perform our current assays, as well as our planned future products,
assays and services, and any problems experienced by them could
result in a delay or interruption of their supply to us; our
commercial success could be compromised if hospitals or other
clients do not pay our invoices or if third-party payers, including
managed care organizations and Medicare, do not provide coverage
and reimbursement, breach, rescind or modify their contracts or
reimbursement policies or delay payments for our current assays and
our planned future assays; and our products and services may not
perform as expected. These and other risks are described in greater
detail under the "Risk Factors" heading of our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2021, as filed with
the Securities and Exchange Commission (SEC) on November 15, 2021.
The effects of such risks and uncertainties could cause actual
results to differ materially from the forward-looking statements
contained in this release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC, which can be accessed over the Internet at the SEC's website
located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122005908/en/
Media Contact: Sampson PR Group Andrea Sampson
asampson@sampsonprgroup.com, (562) 304-0301
Investor Contact: LHA Investor Relations Jody Cain
Jcain@lhai.com, (310) 691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024